amcofen 2.5 mg/25 mg film-coated tablets for small dogs and puppies weighing at least 0.5 kg
krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 2.5,25 mg/tablet - milbemycin oxime, combinations
mektix 12.5 mg/125 mg film-coated tablets for dogs weighing at least 5 kg
krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 12.5,125 mg/tablet - milbemycin oxime, combinations
mektix 2.5 mg/25 mg film-coated tablets for small dogs and puppies weighing at least 0.5 kg
krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 2.5,25 mg/tablet - milbemycin oxime, combinations
milgusto 12.5 mg/125 mg film-coated tablets for dogs weighing at least 5 kg
krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 12.5/125 mg/tablet - milbemycin oxime
milgusto 2.5 mg/25 mg film-coated tablets for small dogs and puppies weighing at least 0.5 kg
krka, d.d., novo mesto - milbemycin oxime; praziquantel - film-coated tablet - 2.5/25 mg/tablet - milbemycin oxime
bexepril 2.5 mg film-coated tablet for dogs
chanelle pharmaceuticals manufacturing limited - benazepril hydrochloride - film-coated tablet - 2.5 mg/tablet - benazepril - dogs - cardiovascular
bexepril 20 mg film-coated tablet for dogs
chanelle pharmaceuticals manufacturing limited - benazepril hydrochloride - film-coated tablet - 20 mg/tablet - benazepril - dogs - cardiovascular
tenofovir disoproxil viatris tenofovir disoproxil maleate 300 mg film coated tablet bottle
alphapharm pty ltd - tenofovir disoproxil maleate, quantity: 300 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hyprolose; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; triacetin; indigo carmine aluminium lake - tenofovir disoproxil viatris in combination with other antiretroviral agents is indicated for the treatment of hiv infected adults and paediatric patients 12 years of age and older.,tenofovir disoproxil viatris is indicated for the treatment of chronic hepatitis b in adults (see clinical trials).,tenofovir disoproxil viatris is indicated for the treatment of chronic hepatitis b in paediatric patients 12 years of age and older with compensated liver disease and with evidence of immune active disease, i.e. active viral replication, persistently elevated serum alt levels or evidence of active inflammation
voriconazole sandoz voriconazole 50mg film-coated tablet blister pack
sandoz pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; triacetin - voriconazole sandoz is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.,- this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration.
voriconazole sandoz voriconazole 200mg film-coated tablet blister pack
sandoz pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; povidone; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; triacetin - voriconazole sandoz is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.,- this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration.